Why the study?
The optimal DAPT duration post-PCI remains unclear, with ongoing concerns regarding bleeding risks linked to long-term potent P2Y12 inhibitors.
Does abbreviated DAPT (≤ 3 months) reduce 1-year all-cause mortality and bleeding compared to conventional DAPT (≥ 12 months) in patients undergoing PCI?
Does abbreviated DAPT (≤ 3 months) reduce 1-year all-cause mortality and bleeding compared to conventional DAPT (≥ 12 months) in patients undergoing PCI?
Abbreviated DAPT (≤ 3 months) post-PCI reduces all-cause mortality and major bleeding compared to conventional DAPT (≥ 12 months) without increasing ischemic events.
Answers are grounded in this paper and cite their sources.
Supports abbreviated DAPT post-PCI to lower mortality and bleeding; confirms RCT benefits in pooled analysis.
BACKGROUND: Dual antiplatelet therapy (DAPT), combining aspirin and a P2Y12 receptor inhibitor, is a standard post-percutaneous coronary intervention (PCI) treatment to reduce thrombosis and ischemic events. However, the optimal DAPT duration remains unclear, with concerns about bleeding risks associated with long-term potent P2Y12 inhibitors. This systematic review and meta-analysis investigates the safety and efficacy of shortened DAPT regimens. METHODS: A comprehensive search of PubMed, Scopus, and EMBASE identified randomized controlled trials (RCTs) comparing conventional DAPT (≥ 12 months) and abbreviated DAPT (≤ 3 months) post-PCI. Primary outcomes were 1-year all-cause mortality and bleeding, assessed using the Bleeding Academic Research Consortium (BARC) classification. Secondary outcomes included cardiovascular mortality, non-fatal myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE). Risk of bias was assessed with the Cochrane tool, and meta-analyses used random-effects models. RESULTS: Forty studies involving 54,233 participants were included. Abbreviated DAPT significantly reduced all-cause mortality (RR: 0.90, 95%CI: 0.82-0.98) and bleeding (BARC 3 or 5: RR: 0.77, 95%CI: 0.60-0.97). No significant differences were observed in cardiovascular mortality, stroke, non-fatal MI, revascularization, or in-stent thrombosis. Subgroup analyses showed lower mortality with 1-month DAPT and reduced bleeding in patients with high bleeding risk, acute coronary syndrome (ACS), and complex PCI. CONCLUSIONS: Abbreviated DAPT post-PCI is associated with lower all-cause mortality and bleeding without compromising ischemic protection, supporting its use in specific patient populations. Individualized DAPT durations should be considered to balance bleeding and ischemic risks.
No takes yet. Share an insight, caveat, or question.
Soleimani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: